MedTrace Logo

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

NCT00639002 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-02-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.

Conditions

Interventions

DRUG

Ruxolitinib 25 mg

Ruxolitinib was supplied as 5 and 25 mg tablets.

DRUG

Dexamethasone 40 mg

Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.

Sponsors & Collaborators

Principal Investigators

  • Sundar Jagannath, MD · St. Vincent's Comprehensive Cancer Center, New York, New York

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00639002 on ClinicalTrials.gov